Company profile
YS Biopharma Co., Ltd.
Delisted (Nasdaq: YS): renamed LakeShore Biopharma, taken private 2026-06-24
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Preclinical / Unstaged | —Vaccine | Infectious Disease Rabies Prevention and Post-Exposure Prophylaxis | |
| Preclinical / Unstaged | —Biologic (subtype unspecified) | Solid Tumors Advanced Solid Tumors |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.